Glaukos Corporation GKOS
Glaukos Corporation (NYSE: GKOS) is an ophthalmology drug developer. Its lead program, RevOpsis multi-specific biologic molecule, is in Pre-clinical for retinal disease (neovascular AMD, diabetic macular edema, retinal vein occlusion). Its next catalyst on record is iLink (third-generation, customized, tomography-guided): Company is preparing to commence Phase 3 clinical program for third-generation customized tomography-guided iLink therapy in 2027. (2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: iLink (third-generation, customized, tomography-guided) — Company is preparing to commence Phase 3 clinical program for third-generation customized tomography-guided iLink therapy in 2027. (2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| iDose TR | glaucoma (sustained-release) | device-combination | Approved |
| Epioxa | keratoconus (corneal cross-linking) | small molecule | Approved |
| iStent family (iStent infinite and others) | glaucoma (MIGS) | device-combination | Approved |
| iLink bioactivation systems | corneal cross-linking (proprietary CXL) | device-combination | Approved |
| Next generation iDose products | glaucoma | device-combination | Pre-clinical |
| Next generation Epioxa products | corneal disorders | small molecule | Pre-clinical |
| RevOpsis additional retinal products (up to four) | retinal disease | biologic-other | Pre-clinical |
Recent results and decisions
- Nov 6, 2026completed enrollment Glaukos completed enrollment in iStent infinite mild-to-moderate study in 2025.
Completed enrollment in iStent infinite mild-to-moderate study
Filing - Nov 6, 2026completed enrollment Glaukos completed patient enrollment in Phase 2 trial of iLution transdermal cream for Demodex blepharitis.
Demodex blepharitis program in Phase 2 clinical stage with completed patient enrollment
Filing - Nov 6, 2026completed enrollment Glaukos completed patient enrollment in Phase 2a first-in-human trial of IVT multi-kinase inhibitor for AMD, DME and RVO.
Patient enrollment is now complete in Phase 2a first-in-human clinical trial of IVT multi-kinase inhibitor program targeting AMD, DME and RVO
Filing
17 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical ophthalmology companies
- Surrozen, Inc. SRZN
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.